| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1080/14712598.2017.1346078 |
| P698 | PubMed publication ID | 28657381 |
| P50 | author | Raimon Sanmarti | Q54263147 |
| María Victoria Hernández | Q57951336 | ||
| Juan D Cañete | Q38523449 | ||
| P2093 | author name string | Ma Victoria Hernández | |
| P2860 | cites work | High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. | Q51607073 |
| Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. | Q53239672 | ||
| Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. | Q53725487 | ||
| Cancer in Patients with Rheumatic Diseases Exposed to TNF Antagonists | Q56966783 | ||
| Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review | Q56966795 | ||
| Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists | Q56966834 | ||
| Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register | Q56969723 | ||
| Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis | Q57753793 | ||
| Potential Effect of Anti-Tumour Necrosis Factor-Alpha Treatment on Reducing the Cardiovascular Risk Related to Rheumatoid Arthritis | Q58418470 | ||
| The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation | Q26765038 | ||
| From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection | Q26770209 | ||
| Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients | Q26829810 | ||
| Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies | Q26991673 | ||
| Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis | Q27691388 | ||
| Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials | Q28084309 | ||
| Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent | Q28191546 | ||
| Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis | Q30357450 | ||
| Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis | Q30420964 | ||
| Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study | Q30571623 | ||
| Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry | Q30645118 | ||
| Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment | Q30811550 | ||
| Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials | Q33243658 | ||
| Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials | Q33315300 | ||
| Abatacept for rheumatoid arthritis: a Cochrane systematic review | Q33524713 | ||
| Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients | Q33765608 | ||
| Cardiovascular morbidity and mortality in rheumatoid arthritis | Q33806651 | ||
| Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR) | Q34056237 | ||
| Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry | Q34065405 | ||
| Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis | Q34327451 | ||
| Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs | Q34369188 | ||
| Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis | Q34498486 | ||
| 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis | Q34500921 | ||
| The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement | Q34660076 | ||
| Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register | Q34758793 | ||
| Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy | Q34908712 | ||
| Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study | Q34923104 | ||
| The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents | Q35082559 | ||
| Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources | Q35318027 | ||
| Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). | Q35350912 | ||
| Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study | Q35352554 | ||
| Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies | Q35554567 | ||
| Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists | Q35554823 | ||
| Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists | Q35554865 | ||
| Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha | Q35555309 | ||
| Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. | Q35590496 | ||
| Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study). | Q35601018 | ||
| Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy | Q35636624 | ||
| Patterns of cardiovascular risk in rheumatoid arthritis | Q35638493 | ||
| Integrated safety in tocilizumab clinical trials | Q35840716 | ||
| Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists | Q36013844 | ||
| The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register | Q36020193 | ||
| Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept | Q36031285 | ||
| Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis | Q36086443 | ||
| Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients | Q36361633 | ||
| Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis | Q36679769 | ||
| Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register | Q36732112 | ||
| A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis | Q36757029 | ||
| Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients | Q37130018 | ||
| Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab | Q37146221 | ||
| Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment | Q37404886 | ||
| Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial | Q37465523 | ||
| Management of RA medications in pregnant patients | Q37511730 | ||
| Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study | Q37715956 | ||
| Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents | Q37838346 | ||
| Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. | Q37915351 | ||
| Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis | Q37925407 | ||
| ??? | Q28080246 | ||
| Skin lesions and treatment with tumor necrosis factor alpha antagonists | Q38024213 | ||
| Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis | Q38080683 | ||
| Abatacept: a review of its use in the management of rheumatoid arthritis | Q38116472 | ||
| Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review | Q38162599 | ||
| Safety of belatacept bridging immunosuppression in hepatitis C-positive liver transplant recipients with renal dysfunction | Q38171681 | ||
| Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial | Q38498967 | ||
| B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use. | Q38569860 | ||
| Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis | Q38745362 | ||
| The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era: Prevention and Management | Q39021255 | ||
| An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy | Q39110166 | ||
| Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis | Q39822865 | ||
| Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection | Q40336301 | ||
| Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol | Q40368548 | ||
| Pregnancy outcomes following exposure to abatacept during pregnancy | Q40696287 | ||
| BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids | Q40838691 | ||
| Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry | Q40864639 | ||
| Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis | Q40961450 | ||
| Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA) | Q42090806 | ||
| Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study | Q42634784 | ||
| Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure | Q42689974 | ||
| Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis | Q43748523 | ||
| Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program | Q43829469 | ||
| Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study | Q44464975 | ||
| Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? | Q44536841 | ||
| Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. | Q44726792 | ||
| Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice | Q44873739 | ||
| Infections in patients with rheumatoid arthritis treated with biologic agents | Q44952372 | ||
| Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report | Q45180236 | ||
| The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials | Q45199573 | ||
| Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study | Q45747892 | ||
| Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients | Q46161838 | ||
| Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases | Q46166151 | ||
| Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists | Q46525959 | ||
| Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. | Q47831413 | ||
| Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu | Q47849023 | ||
| Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). | Q47945239 | ||
| Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: assessed using 3.0 tesla cardiac magnetic resonance imaging. | Q51120090 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 1089-1103 | |
| P577 | publication date | 2017-06-28 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | Safety profile of biological therapies for treating rheumatoid arthritis | |
| P478 | volume | 17 |
| Q88348165 | Abatacept for Treatment of Rheumatoid Arthritis: Special Focus on the Elderly |
| Q55691195 | Bimodal Function of Anti-TNF Treatment: Shall We Be Concerned about Anti-TNF Treatment in Patients with Rheumatoid Arthritis and Heart Failure? |
| Q57033611 | CYLD suppression enhances the pro-inflammatory effects and hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes by enhancing NF-κB activation |
| Q90265650 | Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISA |
| Q43280791 | Tocilizumab: A Review in Rheumatoid Arthritis |
| Q90373577 | [Biologicals and small molecules for rheumatoid arthritis] |
Search more.